Chinese Dental Implant Leader Weigao Jierikang Secures Hundreds of Millions in Series A Funding to Accelerate Growth
VCBeat has learned that WEGO Jielikang Biomaterials Co., Ltd. (hereinafter referred to as “WEGO Jielikang”) has announced the completion of its Series A financing, amounting to hundreds of millions of yuan.This financing round was jointly invested by Zhouji Tongli (under Far East Horizon), Chuangjing Capital, China Merchants Securities Investment, and Weihai Industrial Investment Group, with Life Capital serving as the exclusive financial advisor for this round.
This round of financing will accelerate the company’s capacity expansion, pipeline development, new material R&D, exploration of application scenarios, and scaled mass production of products. Meanwhile, the company will actively seek high-quality targets and partners to further expand WEGO’s influence and competitiveness in the dental implant field through mergers and acquisitions or collaborations, thereby continuing to provide the market with stable, high-quality, and diversified clinical solutions for oral applications.
WEGO Jierikang, a wholly-owned subsidiary of WEGO Group established in 2010, is a high-tech enterprise engaged in the research and development, manufacturing, sales, and training of dental medical devices. Its main products include dental implant systems (WEGO/JERICOM/Xteady), oral biomaterials, digital dental diagnosis and treatment equipment, surgical instruments for implantology, personalized and digital dental restorative products, and clinical dental consumables.
The Company has consistently adhered to a development strategy centered on independent innovation and win-win cooperation. It aims to develop implantable medical devices characterized by high technological content and strong clinical relevance. Guided by the quality policy of “meeting and striving to exceed customers’ utmost needs,” and committed to the mission of “establishing and developing a world-class national brand,” the Company vigorously promotes the integration of industry, academia, and research, as well as the localization of rapid product services. In doing so, it seeks to make new contributions to advancing China’s oral healthcare industry and improving public health.
Dental implantology is a highly specialized and technical field; achieving breakthroughs and maintaining a leading position in this domain requires robust research and development capabilities as well as a spirit of innovation.
As a comprehensive, safe, reliable, and trustworthy provider of total medical system solutions, WEGO Group boasts extensive R&D experience and capabilities across multiple fields, including dentistry, orthopedics, interventional medicine, and nephrology. Incubated under WEGO Group’s R&D system, WEGO Jielikang leverages the group’s resource and platform advantages to establish significant strengths in the research, development, production, and manufacturing of dental implants.
However, for a dental implant to function under load in the open oral environment for decades without infection or loosening, the tolerances for intercomponent connections must be controlled within just a few micrometers. This imposes exceptionally high demands on product design philosophy, material selection, precision machining, and the technological sophistication of surface treatments. Therefore, in addition to maintaining the leading edge of its R&D system, WEGO has continuously engaged in collaborative communication with renowned overseas brands and enterprises throughout the product development process. During key breakthrough phases, the company conducted multiple overseas study visits and established China’s first high-level, fully automated production line for implant systems. This manufacturing capability benchmarks against international brands, thereby ensuring the quality and stability of WEGO products.
In addition, to enter the market, domestic dental implant manufacturers must be supported by extensive accumulation of clinical data. Taking European and American brands as examples, in addition to R&D and manufacturing, academic achievements and case accumulations constitute their competitive moat for market expansion. For this reason, to verify the clinical safety and reliability of its products, WEGO initiated clinical trials simultaneously at the Affiliated Hospital of Qingdao University, Peking University School of Stomatology, and Qingdao Municipal Hospital in late 2011. In 2014, it launched the submerged WEGO Dental Implant System, which possesses fully independent intellectual property rights and has obtained 12 patents, at a price only half that of European and American brands. In 2016, WEGO’s lifetime warranty plan for its dental implant system was launched in Qingdao, making it the first domestically produced implant system to offer a lifetime warranty commitment. The willingness to conduct 10 years of clinical research reflects both the company’s rigor in clinical studies and its confidence in product quality; ultimately, however, this stems from WEGO’s strong confidence in its own technology.
WEGO has consistently adhered to product innovation, establishing long-term and stable collaborative partnerships with numerous prestigious institutions, including Peking University School of Stomatology, West China School of Stomatology of Sichuan University, Wuhan University School of Stomatology, Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences, Shenyang Metal Research Institute, and Northeastern University. Furthermore, the company remains dedicated to research on new materials, continuously iterating its products through sustained clinical exchanges and collaborations, thereby enhancing product quality and clinical performance.
In the future, WEGO will continue to deepen its core business in dental implants, accelerate product innovation and iteration, and simultaneously expand its related product pipeline around the dental implant sector. By exploring the development of products such as oral biomaterials and digital dental equipment, WEGO aims to amplify the voice of domestic implant brands within the industry.
This funding round marks WEGO’s first equity financing from market-oriented investment institutions, reflecting not only the high level of attention professional investors are paying to China’s domestic dental implant industry, but also their strong recognition of WEGO’s solutions and R&D capabilities.
Regarding this round of financing, Mr. Li Dianhua, General Manager of WEGO, stated“This round of financing has laid a solid foundation for the next phase of rapid development at WEGO, ushering in a new chapter. WEGO will strive to lead the domestic dental implant industry, continuously drive innovation, and aim to break the monopoly held by foreign brands in China’s dental implant market, with the goal of becoming the world’s leading supplier of dental implant systems.”
Mr. Peng Haowei, Co-Director of Zhouji Tongli under Far East Horizon, stated“China’s dental implant market has long been monopolized by foreign manufacturers. As a leading domestic brand, Jielikang has remained steadfast for over a decade, earning the trust of both the government and users. It is no small feat that the company won the bid in Group A, Category A—with the highest reported volume among domestic brands—in this centralized procurement process. Jielikang is one of the few companies in China to have established a comprehensive portfolio across all categories of dental implants, and it remains the only domestic brand to have completed a ten-year clinical follow-up study on its implants. This achievement reflects the perseverance, innovation, and commitment of Jielikang’s management team, as well as their emphasis on user experience and clinical value. With the empowerment and support of WEGO Group and its partners, and through the joint efforts of the Jielikang team led by Mr. Li, the company is poised to replicate the path of import substitution seen in other medical device sectors, ultimately becoming the leading domestic dental implant brand that replaces foreign competitors.”
Mr. Song Longtao, Managing Partner of Chuangjing Capital, stated“Leveraging advanced processing equipment, sophisticated testing instruments, and stringent, refined production management, Jielikang ensures stable and reliable product quality, thereby guaranteeing high success rates for dental implants. The dental implant sector represents an essential market with significant potential for expansion into lower-tier regions; it demands both high product quality and affordable pricing. Only enterprises that commit to meticulous operations and continuous innovation can seize this opportunity and establish strong domestic autonomous brands. We believe Jielikang is such an enterprise.”
Qu Long, Head of the Healthcare Investment Team at China Merchants Securities, stated“Backed by the WEGO Group, Jielikang boasts a rich and competitive product portfolio and is the only domestic dental implant company with over 10 years of clinical follow-up data. Leveraging recent policy developments and the centralized procurement of dental implants, Jielikang aims to accelerate the substitution of imported implants with domestically produced alternatives, thereby benefiting the general public and establishing itself as an increasingly trustworthy Chinese brand in the dental implant sector.”
Sylvia Siu, Managing Director of Life Capital, stated“For a long time, the domestic dental implant market has been monopolized by overseas brands. Since its establishment, WEGO Jielikang has consistently adhered to independent research and development and innovation, closely aligning with clinical needs and refining its products through decades of iteration. We are confident that, under the guidance of the centralized procurement policy for dental implants and through the joint efforts of WEGO Group and the Jielikang team, Jielikang will continuously improve and expand its product portfolio, accelerate the substitution of imported dental implants with domestically produced alternatives, and establish Jielikang as a leading Chinese national brand in the dental implant sector.”